NewEdge Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-150
| Closed | -$1.42K | – | 4013 |
|
|
2025
Q1 | $1.42K | Hold |
150
| – | – | ﹤0.01% | 3573 |
|
|
2024
Q4 | $1.85K | Buy |
150
+50
| +50% | +$616 | ﹤0.01% | 3468 |
|
|
2024
Q3 | $1.5K | Hold |
100
| – | – | ﹤0.01% | 3442 |
|
|
2024
Q2 | $1.35K | Hold |
100
| – | – | ﹤0.01% | 3408 |
|
|
2024
Q1 | $1.66K | Hold |
100
| – | – | ﹤0.01% | 3411 |
|
|
2023
Q4 | $1.35K | Hold |
100
| – | – | ﹤0.01% | 3409 |
|
|
2023
Q3 | $1.1K | Buy |
100
+90
| +900% | +$986 | ﹤0.01% | 3161 |
|
|
2023
Q2 | $129 | Hold |
10
| – | – | ﹤0.01% | 3410 |
|
|
2023
Q1 | $120 | Hold |
10
| – | – | ﹤0.01% | 3335 |
|
|
2022
Q4 | $0 | Buy |
+10
| New | – | ﹤0.01% | 4104 |
|